CN108545761B - 一种大孔普鲁士蓝纳米粒及其制备方法 - Google Patents
一种大孔普鲁士蓝纳米粒及其制备方法 Download PDFInfo
- Publication number
- CN108545761B CN108545761B CN201810362520.5A CN201810362520A CN108545761B CN 108545761 B CN108545761 B CN 108545761B CN 201810362520 A CN201810362520 A CN 201810362520A CN 108545761 B CN108545761 B CN 108545761B
- Authority
- CN
- China
- Prior art keywords
- macroporous
- prussian blue
- solution
- blue nanoparticles
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 69
- 229960003351 prussian blue Drugs 0.000 title claims abstract description 69
- 239000013225 prussian blue Substances 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims abstract description 14
- 230000032683 aging Effects 0.000 claims abstract description 12
- 238000001816 cooling Methods 0.000 claims abstract description 12
- 239000011259 mixed solution Substances 0.000 claims abstract description 12
- 238000005406 washing Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000008367 deionised water Substances 0.000 claims abstract description 11
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 11
- 239000003929 acidic solution Substances 0.000 claims abstract description 8
- 229910052742 iron Inorganic materials 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 4
- 239000005416 organic matter Substances 0.000 claims abstract description 3
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 3
- 239000011148 porous material Substances 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- -1 potassium ferricyanide Chemical compound 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000000276 potassium ferrocyanide Substances 0.000 claims description 2
- 239000000264 sodium ferrocyanide Substances 0.000 claims description 2
- GTSHREYGKSITGK-UHFFFAOYSA-N sodium ferrocyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] GTSHREYGKSITGK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012247 sodium ferrocyanide Nutrition 0.000 claims description 2
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 claims description 2
- DCXPBOFGQPCWJY-UHFFFAOYSA-N trisodium;iron(3+);hexacyanide Chemical compound [Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCXPBOFGQPCWJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 239000013335 mesoporous material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- OOIOHEBTXPTBBE-UHFFFAOYSA-N [Na].[Fe] Chemical compound [Na].[Fe] OOIOHEBTXPTBBE-UHFFFAOYSA-N 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010335 hydrothermal treatment Methods 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000026015 thallium poisoning Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01C—AMMONIA; CYANOGEN; COMPOUNDS THEREOF
- C01C3/00—Cyanogen; Compounds thereof
- C01C3/08—Simple or complex cyanides of metals
- C01C3/12—Simple or complex iron cyanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/12—Surface area
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
- C01P2006/17—Pore diameter distribution
Abstract
本发明公开了一种大孔普鲁士蓝纳米粒及其制备方法。该制备方法包括:(1)将铁源和具有还原和稳定作用的有机物加入到酸性溶液S1中,磁搅拌至得到澄清混合溶液;(2)将混合液转至温度为T1℃的烘箱中,陈化H1小时取出,冷却至室温,离心分离,去离子水洗数次,溶于酸性溶液S2中待用;(3)将溶液转移至水热釜,置于温度为T2℃的电炉中,陈化,冷却至室温,离心分离,水洗,干燥,得孔径为3‑20nm范围内的尺寸为20‑200nm大孔普鲁士蓝纳米粒。本发明制备的大孔普鲁士蓝纳米粒具有高度分散、均一的尺寸的特点;且其制备过程简单,原料成本低廉,易调控,方法新颖,具有极其广泛的应用前景。
Description
技术领域
本发明属于纳米材料技术领域,涉及一种大孔普鲁士蓝纳米粒及其制备方法。
背景技术
普鲁士蓝(Prussian blue,PB),作为一种历史悠久的染料,自柏林化学家迪斯巴赫(Diesbach)在1704年意外发现以来,在过去的300多年中引起了极大关注。PB具有可调的尺寸、形态和表面的纳米颗粒,并可控制纳米颗粒的组装,调整其物理和化学性质。由于其电化学、光电化学、磁性和光学性质,PB纳米结构引起了各方面的极大兴趣,其应用包括电池、电致变色显示器、燃料电池、气体存储、传感器和信号增强纳米器件。
介孔材料由于其高的比表面积,大的孔容,可调控的介观结构和孔径尺寸,受到了极大的关注。研究表明,粒径大小和孔径大小都是决定介孔材料应用范围的重要因素,特别是在装载生物大分子,纳米微反应器和催化反应的领域中。例如,生物大分子(如siRNA、DNA等)的尺寸在5-20nm,一般的介孔纳米粒难以实现对其的担载,从而难以实现对基因的保护,对肿瘤进行基因治疗。
目前针对大孔普鲁士蓝纳米粒的合成,鲜有报道。
发明内容
本发明所解决的技术问题是针对上述现有技术中的上述缺陷,提供一种大孔普鲁士蓝纳米粒及其制备方法。
本发明方法首先制备尺寸在20-200nm范围内的普鲁士蓝纳米粒方块,接着对其进行水热处理,制得孔径为3-20nm范围的高分散,尺寸均一可控的大孔普鲁士蓝纳米粒。该方法简单可行,原料成本低。
本发明为解决现有技术中的上述问题提出的。种大孔普鲁士蓝纳米粒及其制备方法
为实现上述目的,本发明采用以下技术方案:
本发明的第一个方面是提供一种大孔普鲁士蓝纳米粒的制备方法,具体包括如下步骤:
(1)将铁源和具有还原和稳定作用的有机物加入到酸性溶液S1中,磁搅拌至得到澄清混合溶液;
(2)将混合液转至温度为T1℃的烘箱中,陈化H1小时取出,冷却至室温,离心分离,去离子水洗数次,溶于酸性溶液S2中待用;
(3)将上述溶液转移至水热釜,置于温度为T2℃的电炉中,陈化适当时间H2小时,取出冷却至室温,离心分离,去离子水洗数次,冷冻干燥,即可获得孔径为3-20nm范围内的尺寸为20-200nm大孔普鲁士蓝纳米粒。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述所述铁源为铁氰化钾、亚铁氰化钾、铁氰化钠和亚铁氰化钠中的至少一种。
进一步优选地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述所述铁源的浓度为0.001M-2M。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述还原剂和稳定剂为聚乙烯吡咯烷酮,海藻酸,表没食子儿茶素没食子酸酯,壳聚糖及其衍生物或淀粉样蛋白中的一种或几种。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述还原剂和稳定剂的浓度为0.001M-10M。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述酸性溶液为盐酸,硝酸,硫酸或磷酸;所述酸性溶液S1的浓度为0.001M-8M;所述酸性溶液S2的浓度为1M-10M。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述温度T1为60-150℃;所述温度T2为25-200℃。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所述时间H1为6-48小时;所述时间H2为1-48小时。
进一步地,在所述的大孔普鲁士蓝纳米粒的制备方法中,所制备的大孔普鲁士蓝纳米粒的化学式为:
AxFey[Fe(CN)6]z(A=Na,K;x:0.3-2.2;y:0.4-2.5;z:0.6-2.8);
其尺寸为20-200nn范围内,孔径为3-20nm。
本发明的第二个方面是提供一种采用上述所述方法制备的大孔普鲁士蓝纳米粒,所述纳米粒的比表面积为200-1000m2g-1,孔容为0.5-5cm3g-1。
本发明的第三个方面是提供一种大孔普鲁士蓝纳米粒作为光声造影剂和光热转换剂在肿瘤诊疗领域中应用,在近红外区域具有强吸收,高的光热转换效率。
本发明的第四个方面是提供一种大孔普鲁士蓝纳米粒作为超声成像造影剂的应用,可以催化过氧化氢产生氧气。
本发明的第五个方面是提供一种可以装载生物大分子的大孔普鲁士蓝纳米粒,其孔径范围为3-20nm,可以装载的生物大分子如siRNA、DNA等。
本发明的第六个方面是提供一种作为药物载体大孔普鲁士蓝纳米粒,如装载抗癌药物等,如盐酸阿霉素、伊立替康等。
本发明采用上述技术方案,与现有技术相比,具有如下技术效果:
本发明提供了一种制备高度分散、尺寸和粒径可调控大孔普鲁士蓝纳米粒的新方法,其制备过程简单,原料成本低廉,易调控,方法新颖;合成的大孔普鲁士蓝纳米粒在药物输运、吸附、分离、催化、电池、肿瘤诊疗方面具有极其广泛的应用前景。
附图说明
图1显示出了本发明的一个实施方式中所得的大孔普鲁士蓝纳米粒的透射电子显微镜(TEM)照片,其孔径为2-5nm;
图2显示出了本发明的一个实施方式中所得的大孔普鲁士蓝纳米粒的透射电子显微镜(TEM)照片,其孔径为5-12nm;
图3显示出了本发明的一个实施方式中所得的大孔普鲁士蓝纳米粒的透射电子显微镜(TEM)照片,其孔径为5-20nm。
具体实施方式
发明涉及一种大孔普鲁士蓝纳米粒的制备方法。所述的大孔普鲁士蓝纳米粒的粒径小,其粒径和孔径可调控,具有高的比表面积和孔容,非常有利于大分子参与的反应,例如石油催化产物等。普鲁士蓝是一种美国食品与药物管理局批准应用于临床上铊中毒的解毒剂,在药物载体方面具有巨大的潜在应用前景,特别是可以装载生物大分子等。合成的大孔普鲁士蓝纳米粒在药物输运、吸附、分离、催化、电池、肿瘤诊疗方面具有极其广泛的应用前景。本发明的合成方法简单易行,方法新颖,成本低,效率高。
所制备的普鲁士蓝纳米粒的化学式为AxFey[Fe(CN)6]z(A=Na,K;x:0.3-2.2;y:0.4-2.5;z:0.6-2.8)。该方法过程简单,原料成本低廉。制备的大孔普鲁士蓝纳米粒,其尺寸在20-200nn范围内,孔径在3-20nm范围内可调控。
本发明所述的大孔普鲁士蓝纳米粒,在近红外区域具有强吸收,高的光热转换效率,可以作为光声造影剂和光热转换剂应用于肿瘤诊疗领域。
本发明所述的大孔普鲁士蓝纳米粒,可以催化过氧化氢产生氧气,作为超声成像造影剂。
本发明所述的大孔普鲁士蓝纳米粒,可以有效清除羟基自由基、超氧阴离子、过氧化氢、活性氮等。
本发明所述的大孔普鲁士蓝纳米粒,孔径范围为3-20nm,可以装载生物大分子,如siRNA、DNA等。
本发明所述的大孔普鲁士蓝纳米粒,可以作为药物载体,装载抗癌药物等,如盐酸阿霉素、伊立替康等。
本发明所述的大孔普鲁士蓝纳米粒,可以作为锂/钠离子电池的电极等。
本发明提供一种制备高度分散、高比表面积、大孔容、小粒径的大孔普鲁士蓝纳米粒的新方法,解决了现有技术中孔径难以调控,孔径小等问题。本发明的制备工艺简答易行,方法新颖,成本低,效率高,在在药物输运、吸附、分离、催化、电池、肿瘤诊疗方面具有极其广泛的应用前景。
图1示出了本发明的一个实施方式中所得的大孔普鲁士蓝纳米粒的TEM照片,可以看出,所制备的大孔普鲁士蓝纳米粒的孔径在2-5nm范围。
图2示出了本发明的一个实施方式中所得的大孔普鲁士蓝纳米粒的TEM照片,可以看出,所制备的大孔普鲁士蓝纳米粒的孔径在5-12nm范围。
图3示出了本发明的一个实施方式中所得的大孔普鲁士蓝纳米粒的TEM照片,可以看出,所制备的大孔普鲁士蓝纳米粒的孔径在5-20nm范围。
下面通过具体实施例对本发明进行详细和具体的介绍,以使更好的理解本发明,但是下述实施例并不限制本发明范围。
实施例1制备小粒径超大孔径普鲁士蓝纳米粒的方法,包括以下步骤:
步骤A)将250-3960mg的铁青化钾和3-35g的聚乙烯吡咯烷酮(PVP)加入到30-100mL浓度为的1-2M盐酸中,磁搅拌至得到澄清混合溶液;
步骤B)将混合液转至80℃的烘箱中,陈化12-20h取出,冷却至室温,离心分离,去离子水洗数次,溶于20-50mL浓度为1-2M的盐酸中待用;
步骤C)将20mL上述溶液转移至水热釜,置于电炉中,120-140℃陈化2-4h,取出冷却至室温,离心分离,去离子水洗数次,冷冻干燥,即可获得孔径为3-20nm范围内的尺寸为30-200nm介孔普鲁士蓝纳米粒。
实施例2制备小粒径超大孔径普鲁士蓝纳米粒的方法,包括以下步骤:
步骤A)将250-3960mg的铁青化钾和3-35g的聚乙烯吡咯烷酮(PVP)加入到30-100mL浓度为的1-2M盐酸中,磁搅拌至得到澄清混合溶液;
步骤B)将混合液转至80℃的烘箱中,陈化12-20h取出,冷却至室温,离心分离,去离子水洗数次,溶于20-50mL浓度为6-10M的盐酸中待用;
步骤C)将20mL上述溶液转移至水热釜,置于电炉中,25-60℃陈化6-10h,取出冷却至室温,离心分离,去离子水洗数次,冷冻干燥,即可获得孔径为3-5nm范围内的尺寸为30-200nm介孔普鲁士蓝纳米粒。
实施例3制备小粒径超大孔径普鲁士蓝纳米粒的方法,包括以下步骤:
步骤A)将1250-8000mg的铁青化钠和3-35g的壳聚糖加入到20-200mL浓度为的1-4M盐酸中,磁搅拌至得到澄清混合溶液;
步骤B)将混合液转至80℃的烘箱中,陈化6-24h取出,冷却至室温,离心分离,去离子水洗数次,溶于20-50mL浓度为6-10M的盐酸中待用;
步骤C)将20mL上述溶液转移至水热釜,置于电炉中,120-140℃陈化1-4h,取出冷却至室温,离心分离,去离子水洗数次,冷冻干燥,即可获得孔径为3-12nm范围内的尺寸为30-100nm介孔普鲁士蓝纳米粒。
以上对本发明的具体实施例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (2)
1.一种大孔普鲁士蓝纳米粒的制备方法,其特征在于,包括步骤:
(1)将铁源和具有还原和稳定作用的有机物加入到酸性溶液S1中,磁搅拌至得到澄清混合溶液;
(2)将混合液转至温度为T1℃的烘箱中,陈化H1小时取出,冷却至室温,离心分离,去离子水洗数次,溶于酸性溶液S2中待用;
(3)将上述溶液转移至水热釜,置于温度为T2℃的电炉中,陈化适当时间H2小时,取出冷却至室温,离心分离,去离子水洗数次,冷冻干燥,即可获得孔径为3-20nm范围内的尺寸为20-200nm大孔普鲁士蓝纳米粒;
其中,所述铁源为铁氰化钾、亚铁氰化钾、铁氰化钠和亚铁氰化钠中的至少一种;
所述铁源的浓度为0.001M-2M;
所述还原剂和稳定剂为聚乙烯吡咯烷酮,海藻酸,表没食子儿茶素没食子酸酯,壳聚糖及其衍生物或淀粉样蛋白中的一种或几种;
所述还原剂和稳定剂的浓度为0.001M-10M;
所述酸性溶液为盐酸,硝酸,硫酸或磷酸;
所述酸性溶液S1的浓度为0.001M-8M;
所述酸性溶液S2的浓度为1M-10M;
所述温度T1为60-150℃;
所述温度T2为25-200℃;
所述时间H1为6-48小时;
所述时间H2为1-48小时;
所制备的大孔普鲁士蓝纳米粒的化学式为:
AxFey[Fe(CN)6]z(A=Na,K;x:0.3-2.2;y:0.4-2.5;z:0.6-2.8),
且其尺寸为20-200nn,孔径为3-20nm。
2.一种如权利要求1所述方法制备的大孔普鲁士蓝纳米粒,其特征在于,所述纳米粒的比表面积为200-1000m2g-1,孔容为0.5-5cm3g-1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810362520.5A CN108545761B (zh) | 2018-04-20 | 2018-04-20 | 一种大孔普鲁士蓝纳米粒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810362520.5A CN108545761B (zh) | 2018-04-20 | 2018-04-20 | 一种大孔普鲁士蓝纳米粒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108545761A CN108545761A (zh) | 2018-09-18 |
CN108545761B true CN108545761B (zh) | 2021-04-27 |
Family
ID=63511998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810362520.5A Active CN108545761B (zh) | 2018-04-20 | 2018-04-20 | 一种大孔普鲁士蓝纳米粒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108545761B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110451525B (zh) * | 2019-08-07 | 2021-05-11 | 清华大学 | 一种快速制备单斜晶结构普鲁士蓝类似物的方法 |
CN111700909B (zh) * | 2020-06-30 | 2022-11-08 | 上海市第六人民医院 | 普鲁士蓝在制备治疗急性胰腺炎的药物中的应用 |
CN111568924B (zh) * | 2020-06-30 | 2022-12-30 | 上海市第六人民医院 | 普鲁士蓝在制备治疗血管再狭窄的药物中的应用 |
CN111632067B (zh) * | 2020-07-16 | 2023-06-23 | 上海市第六人民医院 | 普鲁士蓝在制备治疗骨关节炎的药物中的应用 |
CN113088255B (zh) * | 2021-03-29 | 2022-05-24 | 江南大学 | 一种具有光热性能的超疏水普鲁士蓝纳米颗粒及制备方法 |
CN113827725A (zh) * | 2021-10-22 | 2021-12-24 | 中国农业科学院麻类研究所 | 一种含大麻二酚的纳米复合材料及其制备方法和应用 |
CN114163843B (zh) * | 2021-12-02 | 2022-11-25 | 中国科学院上海硅酸盐研究所 | 一种hmpb的制备方法、普鲁士蓝基荧光探针及其制备方法 |
CN114950533B (zh) * | 2022-03-21 | 2023-10-20 | 湖南农业大学 | 普鲁士蓝纳米花的制备方法及应用、纳米花结构调节方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030104770A1 (en) * | 2001-04-30 | 2003-06-05 | Arch Specialty Chemicals, Inc. | Chemical mechanical polishing slurry composition for polishing conductive and non-conductive layers on semiconductor wafers |
US20100025238A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
CN103948934B (zh) * | 2014-04-09 | 2017-01-18 | 中国科学院过程工程研究所 | 一种基于络合包覆的药物纳米粒制剂及制备方法和用途 |
CN105412927B (zh) * | 2015-12-22 | 2019-01-08 | 哈尔滨工业大学 | 一种具有高光热性能的锰掺杂空心结构普鲁士蓝纳米粒子的制备方法 |
CN106039311B (zh) * | 2016-07-25 | 2019-03-08 | 合肥工业大学 | 基于普鲁士蓝的光热-化疗联合治疗剂及其制备方法 |
CN106727432B (zh) * | 2017-03-07 | 2019-05-31 | 上海凌凯医药科技有限公司 | 一种类普鲁士蓝纳米颗粒及其制备方法与应用 |
-
2018
- 2018-04-20 CN CN201810362520.5A patent/CN108545761B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN108545761A (zh) | 2018-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108545761B (zh) | 一种大孔普鲁士蓝纳米粒及其制备方法 | |
Cao et al. | Ultrasmall nanozymes isolated within porous carbonaceous frameworks for synergistic cancer therapy: enhanced oxidative damage and reduced energy supply | |
Wang et al. | One-pot synthesis of Fe3O4 nanoparticle loaded 3D porous graphene nanocomposites with enhanced nanozyme activity for glucose detection | |
Lian et al. | Highly biocompatible, hollow coordination polymer nanoparticles as cisplatin carriers for efficient intracellular drug delivery | |
Wang et al. | Engine-trailer-structured nanotrucks for efficient nano-bio interactions and bioimaging-guided drug delivery | |
Wang et al. | Autofluorescent and pH-responsive mesoporous silica for cancer-targeted and controlled drug release | |
Zakaria et al. | Prussian blue derived nanoporous iron oxides as anticancer drug carriers for magnetic‐guided chemotherapy | |
Xie et al. | Intervention of polydopamine assembly and adhesion on nanoscale interfaces: State‐of‐the‐art designs and biomedical applications | |
Zhang et al. | A hybrid nanomaterial with NIR-induced heat and associated hydroxyl radical generation for synergistic tumor therapy | |
WO2020087867A1 (zh) | 一种金属-核酸纳米颗粒及其制备方法和用途 | |
Tang et al. | Dual active nanozyme-loaded MXene enables hyperthermia-enhanced tumor nanocatalytic therapy | |
Song et al. | Fabrication of the biomimetic DOX/Au@ Pt nanoparticles hybrid nanostructures for the combinational chemo/photothermal cancer therapy | |
Dai et al. | SiO2-coated magnetic nano-Fe3O4 photosensitizer for synergistic tumour-targeted chemo-photothermal therapy | |
Zhou et al. | Integration of simultaneous and cascade release of two drugs into smart single nanovehicles based on DNA-gated mesoporous silica nanoparticles | |
Chen et al. | Thermo-sensitively and magnetically ordered mesoporous carbon nanospheres for targeted controlled drug release and hyperthermia application | |
Cheng et al. | Cu-doped cerium oxide-based nanomedicine for tumor microenvironment-stimulative chemo-chemodynamic therapy with minimal side effects | |
Feng et al. | Prussian blue nanoparticles having various sizes and crystallinities for multienzyme catalysis and magnetic resonance imaging | |
CN112843250B (zh) | 一种用于肿瘤铁死亡-气体协同治疗的纳米药物及其制备方法 | |
Qu et al. | A redox responsive controlled release system using mesoporous silica nanoparticles capped with Au nanoparticles | |
Chu et al. | Biodegradable iron-doped ZIF-8 based nanotherapeutic system with synergistic chemodynamic/photothermal/chemo-therapy | |
Liang et al. | Nanoplatforms Based on Covalent Organic Frameworks (COFs) for Biomedical Applications | |
CN113332426B (zh) | 一种硅载体内负载铁单原子的纳米治疗剂的制备方法、由此得到的纳米治疗剂及其应用 | |
Shao et al. | Mn-doped single atom nanozyme composited Au for enhancing enzymatic and photothermal therapy | |
Hu et al. | Precisely NIR-II-activated and pH-responsive cascade catalytic nanoreactor for controlled drug release and self-enhanced synergetic therapy | |
Li et al. | Photothermal/nitric oxide synergistic anti-tumour therapy based on MOF-derived carbon composite nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |